Bryan Garnier - Bic (BB) BIC: new CEO found

Report

Bryan Garnier

Cédric Rossi

BIC: new CEO found

Yesterday evening, BIC announced the appointment of Rob Versloot as CEO, effective 15th September. Rob Versloot has 30+ years of experience in the FMCG sector, including Danone and Hero Group where he was appointed as CEO in 2012. The choice of an "external" profile, rare at BIC, does not surprise

12/06/2025 1 EN

Underlying

Bic

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Cédric Rossi

Other Reports on these Companies

Bryan Garnier

On the shelves now: Consumer Weekly #67

In this Consumer Weekly newsletter, we provide a brief overview of the key factors affecting our Consumer coverage, from Luxury & Consumer goods to Retail & E-commerce and Food & Ingredients. This week, we look at the largest beauty groups in the world. Happy reading!

April 28, 2025 April 28, 2025 1 EN

Bryan Garnier

BIC forced to cut FY25 outlook after a perfect storm in Q1

We were bracing for severe turbulence in Q1 due to the weak retail environment in the US and a demanding comparison base for the rest of the world, but these headwinds proved to be more painful than expected (-10.9% LFL vs. CSSe of -7.5%), forcing the group to cut its FY25 outlook for sales (0-3% F

April 24, 2025 April 24, 2025 1 EN

BioInvent: Updated ph2a data on BI-1808 in CTCL shared at EHA

At EHA, BioInvent shared updated phase 2a data on BI-1808 in CTCL. Among 9 evaluable CTCL patients (7 SS, 2 MF), results showed 1 CR (SS), 3 PRs (2 SS, 1 MF), and 5 SDs - resulting in an ORR of c. 45% and a DCR of 100%. In PTCL, 2 patients were evaluable with 1 PR and 1 SD. On the safety front, all

4h / 43m 4h / 43m 1 EN

Cédric Rossi

Cédric Rossi

Inditex: normalised, not neutralised (cancel & replace)

Whereas Q1 results broadly met expectations, current trading was again underwhelming, with sales from 1st May to 9th June up 6% FX-n (vs. CSSe c.+7%), reflecting volatile demand and a tough comp base. We have trimmed our FY25 estimates by 3% to account for the ongoing normalisation phase and a more

June 12, 2025 June 12, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

BIC: new CEO found

On the shelves now: Consumer Weekly #67

BIC forced to cut FY25 outlook after a perfect storm in Q1

BioInvent: Updated ph2a data on BI-1808 in CTCL shared at EHA

Inditex: normalised, not neutralised (cancel & replace)

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe